Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther October 1 2014 13 (10) 2251-2251;

Small Molecule Therapeutics

  • Small Molecule Therapeutics
    The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
    Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Horn, Youyan Zhang, Sean G. Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann and Sheng-Bin Peng
    Mol Cancer Ther October 1 2014 13 (10) 2253-2263; DOI:10.1158/1535-7163.MCT-14-0257

  • Small Molecule Therapeutics
    Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth
    Krishnendu Pal, Alexandre A. Pletnev, Shamit K. Dutta, Enfeng Wang, Ruizhi Zhao, Aradhita Baral, Vinod Kumar Yadav, Suruchi Aggarwal, Soundararajan Krishnaswamy, Khalid M. Alkharfy, Shantanu Chowdhury, Mark R. Spaller and Debabrata Mukhopadhyay
    Mol Cancer Ther October 1 2014 13 (10) 2264-2275; DOI:10.1158/1535-7163.MCT-14-0291

  • Small Molecule Therapeutics | AuthorChoice
    Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor
    Ziyan Y. Pessetto, Yan Ma, Jeff J. Hirst, Margaret von Mehren, Scott J. Weir and Andrew K. Godwin
    Mol Cancer Ther October 1 2014 13 (10) 2276-2287; DOI:10.1158/1535-7163.MCT-14-0043

  • Small Molecule Therapeutics
    Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer
    Melissa A. Babcook, Sanjeev Shukla, Pingfu Fu, Edwin J. Vazquez, Michelle A. Puchowicz, Joseph P. Molter, Christine Z. Oak, Gregory T. MacLennan, Chris A. Flask, Daniel J. Lindner, Yvonne Parker, Firouz Daneshgari and Sanjay Gupta
    Mol Cancer Ther October 1 2014 13 (10) 2288-2302; DOI:10.1158/1535-7163.MCT-14-0451

  • Small Molecule Therapeutics
    The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
    Michael D. Arensman, Donatello Telesca, Anna R. Lay, Kathleen M. Kershaw, Nanping Wu, Timothy R. Donahue and David W. Dawson
    Mol Cancer Ther October 1 2014 13 (10) 2303-2314; DOI:10.1158/1535-7163.MCT-13-1005

  • Small Molecule Therapeutics
    BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
    Warren Fiskus, Sunil Sharma, Jun Qi, Bhavin Shah, Santhana G.T. Devaraj, Christopher Leveque, Bryce P. Portier, Swaminathan Iyer, James E. Bradner and Kapil N. Bhalla
    Mol Cancer Ther October 1 2014 13 (10) 2315-2327; DOI:10.1158/1535-7163.MCT-14-0258

  • Small Molecule Therapeutics
    Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
    Raghavendra Gowda, SubbaRao V. Madhunapantula, Arati Sharma, Omer F. Kuzu and Gavin P. Robertson
    Mol Cancer Ther October 1 2014 13 (10) 2328-2340; DOI:10.1158/1535-7163.MCT-14-0357

Large Molecule Therapeutics

  • Large Molecule Therapeutics
    Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
    Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien-Hsing Chang and David M. Goldenberg
    Mol Cancer Ther October 1 2014 13 (10) 2341-2351; DOI:10.1158/1535-7163.MCT-14-0345

  • Large Molecule Therapeutics
    Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
    Christopher L. Daige, Jason F. Wiggins, Leslie Priddy, Terri Nelligan-Davis, Jane Zhao and David Brown
    Mol Cancer Ther October 1 2014 13 (10) 2352-2360; DOI:10.1158/1535-7163.MCT-14-0209

Cancer Biology and Signal Transduction

  • Cancer Biology and Signal Transduction
    Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
    Isabel R. Schlaepfer, Leah Rider, Lindsey Ulkus Rodrigues, Miguel A. Gijón, Colton T. Pac, Lina Romero, Adela Cimic, S. Joseph Sirintrapun, L. Michael Glodé, Robert H. Eckel and Scott D. Cramer
    Mol Cancer Ther October 1 2014 13 (10) 2361-2371; DOI:10.1158/1535-7163.MCT-14-0183

  • Cancer Biology and Signal Transduction
    Prostate Cancer Cell Response to Paclitaxel Is Affected by Abnormally Expressed Securin PTTG1
    Carolina Castilla, M. Luz Flores, Rafael Medina, Begoña Pérez-Valderrama, Francisco Romero, María Tortolero, Miguel A. Japón and Carmen Sáez
    Mol Cancer Ther October 1 2014 13 (10) 2372-2383; DOI:10.1158/1535-7163.MCT-13-0405

  • Cancer Biology and Signal Transduction
    Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs
    Laurence Booth, Jane L. Roberts, Nichola Cruickshanks, Steven Grant, Andrew Poklepovic and Paul Dent
    Mol Cancer Ther October 1 2014 13 (10) 2384-2398; DOI:10.1158/1535-7163.MCT-14-0172

  • Cancer Biology and Signal Transduction
    Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 Expression in Glioblastoma Cells
    Jessian L. Munoz, Vivian Rodriguez-Cruz, Steven J. Greco, Vipul Nagula, Kathleen W. Scotto and Pranela Rameshwar
    Mol Cancer Ther October 1 2014 13 (10) 2399-2411; DOI:10.1158/1535-7163.MCT-14-0011

  • Cancer Biology and Signal Transduction | AuthorChoice
    BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine
    Rebecca M. Jones, Panagiotis Kotsantis, Grant S. Stewart, Petra Groth and Eva Petermann
    Mol Cancer Ther October 1 2014 13 (10) 2412-2421; DOI:10.1158/1535-7163.MCT-13-0862

  • Cancer Biology and Signal Transduction
    Piperlongumine Chemosensitizes Tumor Cells through Interaction with Cysteine 179 of IκBα Kinase, Leading to Suppression of NF-κB–Regulated Gene Products
    Jia Gang Han, Subash C. Gupta, Sahdeo Prasad and Bharat B. Aggarwal
    Mol Cancer Ther October 1 2014 13 (10) 2422-2435; DOI:10.1158/1535-7163.MCT-14-0171

  • Cancer Biology and Signal Transduction
    Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46
    Ute Jungwirth, Johannes Gojo, Theresa Tuder, Gernot Walko, Martin Holcmann, Thomas Schöfl, Karin Nowikovsky, Nastasia Wilfinger, Sushilla Schoonhoven, Christian R. Kowol, Rosa Lemmens-Gruber, Petra Heffeter, Bernhard K. Keppler and Walter Berger
    Mol Cancer Ther October 1 2014 13 (10) 2436-2449; DOI:10.1158/1535-7163.MCT-14-0087

Models and Technologies

  • Models and Technologies
    An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
    Jonathan W. Astin, Stephen M.F. Jamieson, Tiffany C.Y. Eng, Maria V. Flores, June P. Misa, Annie Chien, Kathryn E. Crosier and Philip S. Crosier
    Mol Cancer Ther October 1 2014 13 (10) 2450-2462; DOI:10.1158/1535-7163.MCT-14-0469-T

  • Models and Technologies
    Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
    Ningning He, Nayoung Kim, Mee Song, Choa Park, Somin Kim, Eun Young Park, Hwa Young Yim, Kyunga Kim, Jong Hoon Park, Keun Il Kim, Fan Zhang, Gordon B. Mills and Sukjoon Yoon
    Mol Cancer Ther October 1 2014 13 (10) 2463-2473; DOI:10.1158/1535-7163.MCT-14-0297

Back to top
PreviousNext
Molecular Cancer Therapeutics: 13 (10)
October 2014
Volume 13, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
  • Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
  • The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
  • Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth

Jump to

  • Highlights
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Cancer Biology and Signal Transduction
  • Models and Technologies
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • SLFN11 Expression in Prostate Cancer
  • Single-cell RNA-seq to Uncover Metastatic Targets in PDAC
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • ARX788 Efficacy in HER2-low and T-DM1–resistant Cancers
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement